Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 3/20 | 0.47 |
| ▸ | PDE4A | P27815 | 2/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.41 |
| ▸ | STS | P08842 | 1/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.40 |
| ▸ | CACNB4 | O00305 | 1/20 | 0.40 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.40 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.40 |
| ▸ | CACNG3 | O60359 | 1/20 | 0.40 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.40 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.40 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.40 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.40 |
| ▸ | CACNG7 | P62955 | 1/20 | 0.40 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30009045 | 1.00 | PDE4B (0.47) | PDE4BPDE4APDE4CPDE4DGPR119 | |
| SCHEMBL24735127 | 0.92 | CRBN (0.47) | PDE4BPDE4APDE4CPDE4DCRBN | |
| SCHEMBL30158207 | 0.92 | CRBN (0.47) | PDE4BPDE4APDE4CPDE4DCRBN | |
| SCHEMBL30278930 | 0.90 | PDE4A (0.45) | PDE4BPDE4APDE4CPDE4DGPR119 | |
| SCHEMBL23134748 | 0.90 | PDE4B (0.40) | PDE4BPDE4APDE4CPDE4DGPR119 | |
| SCHEMBL21409182 | 0.90 | KMT2A (0.50) | PDE4BPDE4APDE4CPDE4DCRBN | |
| SCHEMBL23122937 | 0.89 | CRBN (0.42) | GPR119CRBNDDB1ABL1RIN1 | |
| SCHEMBL30009009 | 0.89 | CRBN (0.42) | GPR119CRBNDDB1ABL1RIN1 | |
| SCHEMBL24735228 | 0.89 | MEN1 (0.51) | PDE4BPDE4APDE4CPDE4DCRBN | |
| SCHEMBL29190407 | 0.89 | CRBN (0.45) | PDE4BPDE4APDE4CPDE4DCRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4166557-B1 | INTERMEDIATES OF N-(3-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PHENYL)BENZAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2026-05-06 | — | — | EP | disclosed |
| EP-4467549-A2 | INTERMEDIATES OF N-(3-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PHENYL)BENZAMIDE DERIVATIVES | Novartis AG (CH) | 2024-11-27 | — | — | EP | disclosed |
| US-20240382600-A1 | BIFUNCTIONAL DEGRADERS COMPRISING A TEAD BINDER | NOVARTIS AG (CH) | 2024-11-21 | — | — | US | disclosed |
| EP-4395828-A1 | BIFUNCTIONAL DEGRADERS COMPRISING A TEAD BINDER | Novartis AG (CH) | 2024-07-10 | — | — | EP | disclosed |
| US-20240158399-A1 | N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide Derivatives | NOVARTIS AG (CH) | 2024-05-16 | — | — | US | disclosed |
| EP-4166557-A1 | INTERMEDIATES OF N-(3-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PHENYL)BENZAMIDE DERIVATIVES | Novartis AG (CH) | 2023-04-19 | — | — | EP | disclosed |
| US-11613543-B2 | Substituted pyrrolo[2,3-d]pyrimidines as Bruton's Tyrosine Kinase inhibitors | NOVARTIS AG (CH) | 2023-03-28 | — | — | US | disclosed |
| WO-2023031801-A1 | BIFUNCTIONAL DEGRADERS COMPRISING A TEAD BINDER | NOVARTIS AG (CH) | 2023-03-09 | — | — | WO | disclosed |
| WO-2021055295-A1 | BRD9 BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2021-03-25 | — | — | WO | disclosed |
| EP-3774804-A1 | N-(3-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PHENYL)BENZAMIDE DERIVATIVES | Novartis AG (CH) | 2021-02-17 | — | — | EP | disclosed |
| US-20210002285-A1 | N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide Derivatives | NOVARTIS PHARMA AG (CH) | 2021-01-07 | — | — | US | disclosed |
| WO-2019186343-A1 | N-(3-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PHENYL)BENZAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2019-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240382600-A1 | BIFUNCTIONAL DEGRADERS COMPRISING A TEAD BINDER | YAP1, JMJD7, TOR1AIP1 | PDE4B 4714/4885PDE4A 4704/4885PDE4C 4723/4885 |
| US-20240158399-A1 | N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide Derivatives | PAH, REN, PKD1 | PDE4B 369/4885PDE4A 422/4885PDE4C 316/4885 |
| US-20210002285-A1 | N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide Derivatives | PAH, PARK7, PKD1 | PDE4B 326/4885PDE4A 387/4885PDE4C 277/4885 |
| US-11613543-B2 | Substituted pyrrolo[2,3-d]pyrimidines as Bruton's Tyrosine Kinase inhibitors | BTK, ABL1, JAK1 | PDE4B 1028/4885PDE4A 1081/4885PDE4C 847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.